FDA Issues Complete Response Letter for Nivolumab in BRAF-Mutant Melanoma
The FDA has requested additional data for the use of single-agent nivolumab in previously untreated patients with BRAF V600 mutation-positive advanced melanoma.
Oncolytic Immunotherapies Show Benefit in Combinations and as Single Agents in Melanoma
Robert Andtbacka, MD, discusses how the role of oncolytic immunotherapies continues to evolve in melanoma and gives a better understanding of what is on the horizon for the novel therapeutics.
European Commission Approves Vemurafenib/Cobimetinib Combo for Melanoma
The European Commission has approved the combination of vemurafenib (Zelboraf) and cobimetinib (Cotellic) as a treatment for patients with BRAF-positive metastatic or unresectable melanoma.
Dramatic Changes Underway in TNBC Treatment Landscape
The treatment paradigm for patients with triple-negative breast cancer is set to undergo a dramatic transformation, as standard chemotherapeutic approaches are perfected and novel antibody-drug conjugates are developed.
Missense HER2 Mutations May Not Respond to Targeted Therapies
Not all HER2 genes are capable of causing cancer growth or spread, and thus may also fail to predict response to anticancer drugs that target the gene.
Promising Adjuvant Therapies Emerge in HER2+ Breast Cancer
Mohammad Jahanzeb, MD, discusses emerging strategies in the adjuvant treatment of patients with HER2-positive breast cancer.
FDA Approves Necitumumab for Squamous NSCLC
The FDA has approved necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2015
Intellisphere, LLC. All Rights Reserved.